Latest News - Regeneron

Tuesday, November 06, 2018

US FDA Grants Dupixent Priority Review for Moderate-to-Severe AD in Adolescents

The US Food and Drug Administration (FDA) has granted Priority Review for Dupixent (dupilumab) as a potential treatment for adolescents with uncontrolled moderate-to-severe atopic dermatitis (AD). …

Read the full story

Friday, September 28, 2018

FDA Approves Regeneron's Libtayo, First Treatment for Metastatic or Locally Advanced SCC

Libtayo (cemiplimab-rwlc) injection (Regeneron Pharmaceuticals, Inc.)  is now FDA-approved for intravenous use for the treatment of patients with metastatic cutaneous squamous cell carcinoma…

Read the full story

Wednesday, May 16, 2018

Dupixent Improves Moderate-to-Severe Atopic Dermatitis in Adolescents

DUPIXENT (dupilumab) performed well in a Phase 3 Trial of inadequately controlled moderate-to-severe atopic dermatitis in adolescents, Regeneron and Sanofi report. In the trial, treatment with…

Read the full story

Tuesday, May 01, 2018

FDA Agrees to Priority Review of Cemiplimab for Advanced Squamous Cell Carcinoma

The FDA has accepted the Biologics License Application (BLA) for cemiplimab for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or patients with locally advance…

Read the full story

Tuesday, February 20, 2018

Asthma and Allergy Foundation Study Shows High Prevalence and QoL Impact for Adults with Atopic Dermatitis

The Asthma and Allergy Foundation of America (AAFA) shared data demonstrating the high rate of prevalence of atopic dermatitis (AD) in the US adult population and a greater impact on health-related qu…

Read the full story

Wednesday, January 17, 2018

GlobalData: Promising Future Forecasted for Dupixent

Regeneron Pharmaceuticals and Sanofi Genzyme’s Dupixent is currently the most successful biologic treatment for moderate-to-severe atopic dermatitis on the market, according to GlobalData. Th…

Read the full story

Monday, September 18, 2017

EADV News: Positive Study Results for Dupixent® (dupilumab) in Patients With Moderate-to-Severe AD

Dupixent with topical corticosteroids (TCS) significantly improved measures of overall disease severity, skin clearing, itching, and patient reported quality of life measure in adults with moderate-to…

Read the full story

Friday, September 08, 2017

Cemiplimab Receives FDA Breakthrough Therapy Designation for Advanced Cutaneous Squamous Cell Carcinoma

The FDA has granted Breakthrough Therapy designation status to Regeneron Pharmaceuticals, Inc. and Sanofi's cemiplimab (REGN2810) for the treatment of adults with metastatic cutaneous squamou…

Read the full story

Tuesday, March 28, 2017

FDA Approves New Eczema Drug Dupixent

The FDA has approved Dupixent (dupilumab) injection to treat adults with moderate-to-severe eczema (atopic dermatitis). Regeneron Pharmaceuticals, Inc.'s Dupixent is intended for patients whose ec…

Read the full story

Wednesday, October 05, 2016

New Survey: AD Is More Than Skin Deep

American adults with atopic dermatitis (AD) report issues with sleep, ability to work and feelings of depression and anxiety, a new survey shows. The findings are significant for clinicians, such as N…

Read the full story

Monday, October 03, 2016

Regeneron and Sanofi's AD Drug Dupilumab Performs Well in Phase III Studies

Dupilumab improves the signs and symptoms of atopic dermatitis including pruritus, anxiety/depression symptoms, and quality of life, according to two Phase III clinical trials published in t…

Read the full story

Monday, September 26, 2016

Regeneron and Sanofi's Dupilumab Biologics License Application Accepted for Priority Review by FDA

The FDA has accepted for priority review the Biologics License Application (BLA) for dupilumab from Regeneron Pharmaceuticals, Inc. and Sanofi for the treatment of adult patients with inadequately con…

Read the full story

Monday, June 06, 2016

Dupilumab with Topical Corticosteroids (TCS) Superior to TCS Alone in Long-term Atopic Dermatitis Study

Treatment with investigational dupilumab in combination with topical corticosteroids (TCS) significantly improved measures of overall disease severity, according to one-year results of the LIBERTY AD …

Read the full story

Friday, April 01, 2016

Next Stop FDA Approval? Dupilumab Improves Symptoms in Moderate-to-Severe AD

Dupilumab helps improve the signs and symptoms of moderate-to-severe atopic dermatitis (AD) in adults, according to two late stage clinical trials. The U.S. Food and Drug Administration (FDA) grant…

Read the full story